Biofrontera Completes Phase 2b Study of Ameluz for Acne Vulgaris
August 25, 2025
Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion Biofrontera Inc. a biopharmaceutical company specializing in the development